Multivariate analysis by Cox proportional hazards model on diffuse large B-cell lymphoma
| Category . | Estimate (value ± SE) . | P value . | Hazards ratio . |
|---|---|---|---|
| Overall survival | |||
| nm23-H1 (< 12.01/≥ 12.01 ng/mL) | 1.51 ± 0.45 | .0007 | 4.571 |
| Soluble IL-2R (< 1000/≥ 1000 U/mL) | 0.72 ± 0.41 | .0810 | 2.038 |
| IPI (L, L-I/H-I, H) | 0.66 ± 0.49 | .1797 | 1.941 |
| Performance status (0, 1/2-4) | 0.56 ± 0.33 | .0841 | 1.757 |
| Extranodal sites (≤ 1/> 1) | 0.47 ± 0.39 | .2370 | 1.592 |
| LDH (normal/>normal) | 0.43 ± 0.42 | .3066 | 1.544 |
| Stage (I, II/III, IV) | 0.41 ± 0.41 | .3103 | 1.514 |
| Age (< 60/≥ 60 yr) | 0.38 ± 0.38 | .3130 | 1.468 |
| Soluble CD44 (< 500/≥ 500 ng/mL) | 0.20 ± 0.30 | .4948 | 1.224 |
| B symptoms | −0.55 ± 0.34 | .1061 | 0.578 |
| Progression-free survival | |||
| nm23-H1 (< 12.01/≥ 12.01 ng/mL) | 0.86 ± 0.36 | .0157 | 2.373 |
| Soluble IL-2R (< 1000/≥ 1000 U/mL) | 0.67 ± 0.38 | .0778 | 1.945 |
| Stage (I, II/III, IV) | 0.59 ± 0.41 | .1502 | 1.797 |
| LDH (normal/> normal) | 0.48 ± 0.42 | .2480 | 1.617 |
| Extranodal sites (≤ 1/> 1) | 0.38 ± 0.45 | .4090 | 1.455 |
| Age (< 60/≥ 60 yr) | 0.35 ± 0.37 | .3361 | 1.421 |
| Soluble CD44 (< 500/≥ 500 ng/mL) | 0.29 ± 0.29 | .3125 | 1.343 |
| IPI (L, L-I/H-I, H) | 0.27 ± 0.47 | .6320 | 1.254 |
| Performance status (0, 1/2-4) | 0.11 ± 0.35 | .7554 | 1.116 |
| B symptoms | −0.33 ± 0.34 | .3306 | 0.717 |
| Category . | Estimate (value ± SE) . | P value . | Hazards ratio . |
|---|---|---|---|
| Overall survival | |||
| nm23-H1 (< 12.01/≥ 12.01 ng/mL) | 1.51 ± 0.45 | .0007 | 4.571 |
| Soluble IL-2R (< 1000/≥ 1000 U/mL) | 0.72 ± 0.41 | .0810 | 2.038 |
| IPI (L, L-I/H-I, H) | 0.66 ± 0.49 | .1797 | 1.941 |
| Performance status (0, 1/2-4) | 0.56 ± 0.33 | .0841 | 1.757 |
| Extranodal sites (≤ 1/> 1) | 0.47 ± 0.39 | .2370 | 1.592 |
| LDH (normal/>normal) | 0.43 ± 0.42 | .3066 | 1.544 |
| Stage (I, II/III, IV) | 0.41 ± 0.41 | .3103 | 1.514 |
| Age (< 60/≥ 60 yr) | 0.38 ± 0.38 | .3130 | 1.468 |
| Soluble CD44 (< 500/≥ 500 ng/mL) | 0.20 ± 0.30 | .4948 | 1.224 |
| B symptoms | −0.55 ± 0.34 | .1061 | 0.578 |
| Progression-free survival | |||
| nm23-H1 (< 12.01/≥ 12.01 ng/mL) | 0.86 ± 0.36 | .0157 | 2.373 |
| Soluble IL-2R (< 1000/≥ 1000 U/mL) | 0.67 ± 0.38 | .0778 | 1.945 |
| Stage (I, II/III, IV) | 0.59 ± 0.41 | .1502 | 1.797 |
| LDH (normal/> normal) | 0.48 ± 0.42 | .2480 | 1.617 |
| Extranodal sites (≤ 1/> 1) | 0.38 ± 0.45 | .4090 | 1.455 |
| Age (< 60/≥ 60 yr) | 0.35 ± 0.37 | .3361 | 1.421 |
| Soluble CD44 (< 500/≥ 500 ng/mL) | 0.29 ± 0.29 | .3125 | 1.343 |
| IPI (L, L-I/H-I, H) | 0.27 ± 0.47 | .6320 | 1.254 |
| Performance status (0, 1/2-4) | 0.11 ± 0.35 | .7554 | 1.116 |
| B symptoms | −0.33 ± 0.34 | .3306 | 0.717 |
IPI indicates International Prognostic Index; L, low risk; L-I, low-intermediate risk; H-I, high-intermediate risk; H, high risk.